...
首页> 外文期刊>Current Pharmaceutical Design >Editorial [Hot Topic: Anti-Amyloidogenic/Protein-Misfolding Therapies in Amyloidosis and Other Protein-Misfolding Disorders (Executive Editor: Masahito Yamada)]
【24h】

Editorial [Hot Topic: Anti-Amyloidogenic/Protein-Misfolding Therapies in Amyloidosis and Other Protein-Misfolding Disorders (Executive Editor: Masahito Yamada)]

机译:编辑[热门话题:抗淀粉样蛋白/蛋白质在淀粉样症和其他蛋白质误用症的疗法(执行编辑:Masahito Yamada)]]

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Amyloidosis is a pathological condition where proteins with diverse chemical composition are extracellularly deposited asfibrils in the brain, heart, kidney, liver, pancreas, nerves, and other tissues or organs resulting in their serious dysfunctions.Misfolding or conformational changes of normally soluble proteins lead to pathological deposition of fibrillar proteins with across--pleated configuration. In addition to amyloidosis characterized by extracellular fibril deposition, protein-misfolding orconformational disorders include diseases characterized by intracellular deposition of fibrillar structures (inclusion bodies) suchas Lewy body diseases [Parkinson’s disease (PD) and dementia with Lewy bodies (DLB)] and polyglutamine diseases of thebrain.
机译:淀粉样蛋白化是一种病理状况,具有多种化学成分的蛋白质是细胞外沉积的大脑中的原纤维,心脏,肾,肝,胰腺,神经和其他组织或器官导致其严重的功能障碍。通常可溶性蛋白质的错误折叠或构象变化导致纤维蛋白的病理沉积交叉褶皱配置。除了淀粉样蛋白沉积的外纤维沉积,蛋白质误用或构象性疾病包括特征的疾病,其细胞内沉积原纤维结构(包涵体)作为Lewy身体疾病[帕金森病(Pd)和痴呆症,具有Lewy Stodies(DLB)]和聚谷氨酰胺疾病脑。

著录项

  • 来源
    《Current Pharmaceutical Design》 |2008年第30期|p.3203-3204|共1页
  • 作者

    Masahito Yamada;

  • 作者单位

    Department of Neurology and Neurobiology of AgingKanazawa University Graduate School of Medical Science13-1 Takara-machiKanazawa 920-8640Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Parkinson’s disease (PD);

    机译:帕金森病(PD);

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号